US prescribers’ attitudes and perceptions about biosimilars
Category: Original Research
90 total, 1 today
Keywords: biosimilars, interchangeability, substitution, switching, US
Author byline as per print journal: Ralph McKibbin, MD; Michael S Reilly, Esq
Introduction: In the United States (US), a legal framework for approving biosimilars was established via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). Now, 37 biosimilars have been approved. Some biosimilars in the US can be designated as ‘interchangeable,’ which means they can be automatically substituted at the pharmacy level. In 2021, the Alliance for Safe Biologic Medicines (ASBM) asked prescribing physicians in the US for their views on the prescribing, substitution and interchangeability of biosimilars.
Methodology: In September 2021, the Alliance for Safe Biologic Medicines (ASBM), conducted a web-based quantitative survey with 401 participants practicing medicine in the US. Prescribers were asked for their views on substitution of, as well as their familiarity with, knowledge of, attitudes to, and beliefs in, biosimilars.
Results: Most physicians are comfortable prescribing biosimilars and comfortable switching stable patients to biosimilar product. Over half of physicians are more likely to prescribe biosimilars with interchangeable status and they are comfortable with pharmacy level substitution of these products. However, the majority want to keep the authority to prevent pharmacy level substitution if they specify so. When it came to switching patients to a biosimilar for non-medical reasons, the majority were comfortable doing this but fewer than half were comfortable with third party switching. In addition, most physicians favored a scenario where multiple products, including innovator and biosimilars are reimbursed, and biosimilars may be encouraged for new patients with no automatic substitution permitted.
Conclusion: The survey reveals that overall, American physicians are confident prescribing biosimilars. It also sheds light on how they feel about the interchangeable designation, and biologic drugs switching choices made by them, pharmacists and payers.
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.
This manuscript has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.